Company news
BioVie Inc. news in 2022
BioVie Inc.'s news releases, calls and decks from 2022, newest first.
BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia
December 5, 2022
BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials
December 4, 2022
BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients
November 28, 2022
BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled
October 18, 2022
BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201
June 22, 2022
BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease
January 19, 2022
Decks in 2022
- Investor Presentation (December 2022)
Investor deck · 47 slides · Dec 7, 2022
- 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Conference · 16 slides · Dec 2, 2022
- Corporate Update (September 2022)
Corporate update · 65 slides · Sep 7, 2022
- Investor Presentation (June 2022)
Investor deck · 33 slides · Jun 29, 2022